Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Adenocarcinoma
ADR ID BADD_A00091
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.16      Miscellaneous and site unspecified neoplasms malignant and unspecified
16.16.01      Neoplasms malignant site unspecified NEC
16.16.01.004      Adenocarcinoma
Description A malignant epithelial tumor with a glandular organization. [MeSH]
MedDRA Code 10001141
MeSH ID D000230; D002288; D003536; D018267
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Adenocarcinoma | Adenocarcinoma NOS | Mucinous carcinoma | Cystadenocarcinoma | Acinic cell carcinoma | Progression of adenocarcinoma | Oxyphilic adenocarcinoma | Carcinoma in adenoma | Adenocarcinomas | Adenoma, Malignant | Adenomas, Malignant | Malignant Adenoma | Malignant Adenomas | Carcinoma, Granular Cell | Carcinomas, Granular Cell | Granular Cell Carcinoma | Granular Cell Carcinomas | Adenocarcinoma, Granular Cell | Adenocarcinomas, Granular Cell | Granular Cell Adenocarcinoma | Granular Cell Adenocarcinomas | Adenocarcinoma, Tubular | Adenocarcinomas, Tubular | Tubular Adenocarcinoma | Tubular Adenocarcinomas | Carcinoma, Tubular | Carcinomas, Tubular | Tubular Carcinoma | Tubular Carcinomas | Carcinoma, Cribriform | Carcinomas, Cribriform | Cribriform Carcinoma | Cribriform Carcinomas | Adenocarcinoma, Basal Cell | Adenocarcinomas, Basal Cell | Basal Cell Adenocarcinoma | Basal Cell Adenocarcinomas | Adenocarcinoma, Oxyphilic | Adenocarcinomas, Oxyphilic | Oxyphilic Adenocarcinoma | Oxyphilic Adenocarcinomas
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00047Afatinib0.000336%
BADD_D00151Apixaban0.000087%
BADD_D00230Bendamustine0.000168%
BADD_D00285Bosentan0.000120%
BADD_D00364Carboplatin0.000224%
BADD_D00414Ceritinib0.000112%
BADD_D00511Clozapine0.002446%
BADD_D00563Dabigatran0.000612%
BADD_D00574Dalfampridine0.000538%
BADD_D00594Deferasirox0.001239%
BADD_D00680Dimethyl fumarate0.000600%
BADD_D00800Erlotinib0.000224%
BADD_D00869Famotidine0.000045%
BADD_D00898Finasteride0.000067%
BADD_D00931Fluorouracil0.000184%
BADD_D00979Furosemide0.000014%
BADD_D01008Gefitinib0.000112%
BADD_D01119Ibrutinib0.000112%
BADD_D01136Imatinib0.000168%
BADD_D01257Letrozole0.000263%
BADD_D01281Levonorgestrel0.000709%
BADD_D01418Methotrexate0.000171%
BADD_D01506Muromonab-cd3--
BADD_D01633Oxaliplatin0.000112%
BADD_D01653Paclitaxel0.000112%
BADD_D01656Paliperidone--
BADD_D01701Pemetrexed0.000112%
BADD_D01783Pirfenidone0.000241%
BADD_D01798Pomalidomide0.000241%
BADD_D01817Pramipexole--
The 1th Page    1 2    Next   Last    Total 2 Pages